Access Over Discount

The offer

IM8's three-month prepaid tier is priced only about 12 percent below the monthly plan, so the discount alone is not what moves buyers up the ladder. As Yeung puts it, "we always try to give value to that consumer" rather than lean on price alone.¹ Subscribers instead get quarterly live Zoom sessions with nine members of IM8's scientific advisory board and performance-training bench, a group Danny Yeung describes as including a 25-year integrative oncologist from the Mayo Clinic and David Beckham's own performance trainer.¹ These are not recorded videos. A customer can ask a live question and get an answer from someone who has trained Beckham or spent a career in oncology.

Yeung frames the pitch as answering two questions a customer could otherwise never get answered: how do you actually train Beckham, and what does a career oncologist think gives someone the best odds of a healthy life. The company's stated ambition is to extend the access beyond scheduled Zoom calls into an always-on digital format.¹

Why access beats a discount

A discount is a transfer. It moves margin from the company to the customer and creates no new value, and it is perfectly copyable, since any competitor can match a price. Access is different: IM8 assembled its scientific advisory board for product-credibility reasons in the first place, so distributing that board's time to subscribers costs the company almost nothing at the margin, while it would cost a competitor years to build the same relationships. It also reinforces the brand's premium positioning rather than undermining it. Discounting a premium supplement quietly concedes the price was inflated; adding expert access argues the opposite, that this is a science-led brand, which is the same claim its clinical trials and its Reputational Risk Is the Partner's Currency partnership structure are already making.

The same instinct runs through IM8's experiential marketing: a "golden ticket to Dubai" draw flew two customers out, with hotels and backstage access, to meet Aryna Sabalenka at an exhibition with Nick Kyrgios. Yeung's summary of the approach: "we don't want to just sell our product. It's about the lifestyle, the community, about how we enrich people with knowledge."¹

Why it matters

The move converts assets a brand acquired for one purpose, credibility and endorsement, into a second, compounding purpose, retention, which is the kind of leverage that stays invisible until someone goes looking for it. It is also a rebuttal to the default DTC instinct to compete on price ladders: once generic information is free, curated access to specific credentialed people becomes the scarce good, and a brand with real relationships can sell what a brand with only inventory cannot.

Three open questions sit underneath the tactic. Scale is unproven: nine advisors on quarterly Zoom calls works at IM8's current subscriber base, but as the company grows, live sessions risk becoming a webinar, at which point the access stops being access, and the proposed always-on digital format may be a quiet admission of that. Take-up is also unmeasured: no public figure exists for how many subscribers actually attend, so the offer could be converting well at the point of purchase while going largely unredeemed, which would be good for margin and bad for the retention thesis it is supposed to serve. A third is regulatory: live question-and-answer sessions between consumers and physicians, hosted by a supplement brand, edge toward individualized medical advice in a category Yeung himself describes as unregulated, and nothing in the record explains how that boundary is managed.